Upperton’s Latest Manufacturing Headquarters: A Leap Towards Pharma Advancement

Upperton Pharma Solutions, a leading UK contract development and manufacturing organization (CDMO), has reached a significant milestone in its expansion journey. The completion of its new development and GMP manufacturing headquarters in Nottingham, UK, marks a giant leap towards meeting larger-scale requirements and supporting a multitude of customer projects. With state-of-the-art equipment and increased operational footprint, Upperton is poised to revolutionize pharmaceutical development and manufacturing.

A Quantum Leap in Infrastructure

Upperton’s new facility is a testament to its commitment to growth and innovation. Spanning 50,000 square feet, the site houses ten advanced GMP manufacturing suites, cutting-edge quality control laboratories, and formulation development capabilities equipped with a pilot plant. This massive expansion increases Upperton’s manufacturing footprint from 1,300 square feet to 13,000 square feet, and analytical laboratory space skyrockets from 880 square feet to 8,500 square feet. The facility’s prowess in handling highly potent and controlled drugs in various dosage forms empowers it to support early formulation development, clinical trial supplies from Phase 1 to Phase 3, and niche-scale commercial manufacture.

Equipped for Pharma Advancements

Upperton’s Nottingham facility has been bolstered by substantial investments in commercial scale equipment, boasting capabilities that will redefine pharmaceutical manufacturing. The array of offerings includes powder blending up to 250 kg per batch, capsule filling up to 40,000 capsules/hour, dry granulation processing up to 100 kg/hour, and tablet pressing up to 120,000 tablets/hour. This cutting-edge equipment ensures efficiency, precision, and scalability, aligning with Upperton’s mission to deliver top-notch pharma solutions.

A Remarkable Journey to Success

Nikki Whitfield, Chief Executive Officer at Upperton, expressed delight in the company’s progress since embarking on this venture in January 2023. The completed facility stands as a testament to Upperton’s substantial growth and promising future. By enhancing its operational scale, the CDMO aspires to offer customers a seamless transition from early development to clinical trials and low-volume niche product commercial manufacturing—all under one roof, supported by established project teams.

Towards Full Operation

With the construction phase concluded, Upperton is now set to commission the facility and commence the installation and validation of its state-of-the-art equipment. The goal is to achieve full operational status for development and non-GMP manufacturing by Q4 of 2023, with GMP operations scheduled to commence in January 2024. As Upperton gears up to serve the pharmaceutical industry with unparalleled capabilities, its new facility promises a bright future for innovative drug development and manufacturing.

About Upperton Pharma Solutions

Upperton Pharma Solutions is a specialized Contract Development and Manufacturing Organization (CDMO) that provides formulation and dosage form development services to the biotechnology and pharmaceutical industries. The company offers a complete development service, ranging from early feasibility studies to process optimization, scale-up, and clinical trial (GMP/IMP) manufacturing. With a strong focus on enhancing product performance and delivery, Upperton Pharma Solutions utilizes an extensive range of formulation technologies. Among these, the company boasts world-leading expertise and know-how in pharmaceutical spray dryings, a versatile and rapidly growing technology within the industry.

Upperton’s expertise extends to a wide range of dosage forms, and the company’s experienced team is well-equipped to handle even the most challenging molecules. To support their formulation work, Upperton offers a comprehensive range of analytical services for product testing and ICH stability studies.

Drawing upon its scientific excellence and flexible approach, Upperton Pharma Solutions serves a diverse multinational client-base, catering to virtual and small start-ups, as well as global pharmaceutical companies. The company takes pride in its client-focused ethos, striving to meet and exceed the unique needs of each partner. As a specialist CDMO, Upperton Pharma Solutions remains at the forefront of pharmaceutical innovation, making significant contributions to the advancement of the biotechnology and pharmaceutical industries worldwide.

Visit upperton.com to learn more.

Engr. Dex Marco Tiu Guibelondo, BS Pharm, RPh, BS CpE

Editor-in-Chief, PharmaFEATURES